Janssen gets EC nod for prostate cancer drug Erleada
Erleada is a next generation oral androgen receptor inhibitor approved to treat adult patients with nmCRPC who are at high risk of developing metastatic disease. Apalutamide holds capacity
The National Medical Products Administration (NMPA) of China has approved Keymed Biosciences’ new drug application granting marketing approval for Stapokibart to treat adults with moderate-to-severe atopic dermatitis.
This is the first time that a multinational pharmaceutical company has gained exclusive authorization in China to promote an innovative drug independently developed by a Chinese pharmaceutical company.
Bioharmony licensed this technology from the Rockefeller University. The discoveries are from the laboratory of Vincent A. Fischetti, Ph.D., a faculty member at The Rockefeller University. Recently, the
Puma Biotechnology filed a new drug submission for NERLYNX® with Health Canada in July 2018 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast